Literature DB >> 22867042

Topical testosterone supplementation for the treatment of male hypogonadism.

Katrina A Abadilla1, Adrian S Dobs.   

Abstract

Age-related hormonal decline is gradual and less recognized in men than in women. Symptoms are oftentimes ignored and non-specific. Fatigue, lack of concentration, mood swings, decreased sexual desire, erectile dysfunction, infertility, hair loss, reduced muscle and bone mass, and weight gain are a few of the symptoms of male hypogonadism. This disorder is linked to reduction in quality of life, and poorer health outcomes as it may increase the risk for cardiovascular disease, diabetes mellitus, metabolic syndrome, Alzheimer's disease and premature death. Different modalities of testosterone replacement therapy have evolved over 70 years, and sales continue to grow. Each preparation is differentiated by route of delivery, ease of use, cost and pharmacokinetics. Topical/transdermal testosterone replacement therapy, including patches and gels, are the most modern formulations on the market. These are more expensive treatments, but yield more physiological concentrations of testosterone. Restoration of testosterone levels to the eugonadal range reverses signs and symptoms of hypogonadism, except for infertility, and may alleviate co-morbidities associated with hypogonadism. Patient understanding of and compliance with both treatment and monitoring are of utmost importance to achieve clinical success with maximum benefit and minimum risk. The aim of our review is to summarize the indications, contraindications, benefits and risks of testosterone replacement therapy as they relate to transdermal administration. Further, we compare the various testosterone preparations, focusing on the newest topical/transdermal routes of administration that are currently available.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22867042     DOI: 10.2165/11635620-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  53 in total

1.  A brief history of testosterone.

Authors:  E R Freeman; D A Bloom; E J McGuire
Journal:  J Urol       Date:  2001-02       Impact factor: 7.450

Review 2.  Review of Testim gel.

Authors:  Tom McNicholas; Teng Ong
Journal:  Expert Opin Pharmacother       Date:  2006-03       Impact factor: 3.889

Review 3.  Androgens in men--uses and abuses.

Authors:  C J Bagatell; W J Bremner
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

Review 4.  Declining gonadal function in elderly men.

Authors:  J M Kaufman; A Vermeulen
Journal:  Baillieres Clin Endocrinol Metab       Date:  1997-07

5.  Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis.

Authors:  Eric Bachman; Rui Feng; Thomas Travison; Michelle Li; Gordana Olbina; Vaughn Ostland; Jagadish Ulloor; Anqi Zhang; Shehzad Basaria; Tomas Ganz; Mark Westerman; Shalender Bhasin
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

6.  Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.

Authors:  A S Dobs; A M Matsumoto; C Wang; M S Kipnes
Journal:  Curr Med Res Opin       Date:  2004-05       Impact factor: 2.580

7.  AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Authors:  C Steidle; S Schwartz; K Jacoby; T Sebree; T Smith; R Bachand
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

8.  American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update.

Authors:  Steven M Petak; Howard R Nankin; Richard F Spark; Ronald S Swerdloff; Luis J Rodriguez-Rigau
Journal:  Endocr Pract       Date:  2002 Nov-Dec       Impact factor: 3.443

9.  Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Authors:  Robert M Coward; Jay Simhan; Culley C Carson
Journal:  BJU Int       Date:  2008-12-23       Impact factor: 5.588

10.  Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

Authors:  T Hugh Jones; Stefan Arver; Hermann M Behre; Jacques Buvat; Eric Meuleman; Ignacio Moncada; Antonio Martin Morales; Maurizio Volterrani; Ann Yellowlees; Julian D Howell; Kevin S Channer
Journal:  Diabetes Care       Date:  2011-03-08       Impact factor: 19.112

View more
  17 in total

1.  Age and testosterone mediate influenza pathogenesis in male mice.

Authors:  Landon G Vom Steeg; Meghan S Vermillion; Olivia J Hall; Ornob Alam; Ross McFarland; Haolin Chen; Barry Zirkin; Sabra L Klein
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-11-04       Impact factor: 5.464

Review 2.  Leydig cells: formation, function, and regulation.

Authors:  Barry R Zirkin; Vassilios Papadopoulos
Journal:  Biol Reprod       Date:  2018-07-01       Impact factor: 4.285

Review 3.  Leydig cell aging and hypogonadism.

Authors:  M C Beattie; L Adekola; V Papadopoulos; H Chen; B R Zirkin
Journal:  Exp Gerontol       Date:  2015-02-18       Impact factor: 4.032

4.  Issues Surrounding Testosterone Replacement Therapy.

Authors:  Carson Schlich; Frank Romanelli
Journal:  Hosp Pharm       Date:  2016-10

5.  Evaluation of an Anhydrous Permeation-Enhancing Vehicle for Percutaneous Absorption of Hormones.

Authors:  Guiyun Song; Daniel Banov; Hui Song; Yi Liu; Kendice Ip; August S Bassani; Benigno C Valdez
Journal:  AAPS PharmSciTech       Date:  2022-07-19       Impact factor: 4.026

Review 6.  Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age.

Authors:  Alexander W Pastuszak; Marc Gittelman; James P Tursi; Jonathan S Jaffe; David Schofield; Martin M Miner
Journal:  Andrology       Date:  2021-10-08       Impact factor: 4.456

7.  Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells.

Authors:  J Y Chung; H Chen; A Midzak; A L Burnett; V Papadopoulos; B R Zirkin
Journal:  Endocrinology       Date:  2013-03-22       Impact factor: 4.736

Review 8.  The practical management of testosterone deficiency in men.

Authors:  Antonio Aversa; Abraham Morgentaler
Journal:  Nat Rev Urol       Date:  2015-10-13       Impact factor: 14.432

9.  The effect of metabolic syndrome upon the success of varicocelectomy.

Authors:  Ufuk Ozturk; Nevzat Can Sener; Ismail Nalbant; Osman Raif Karabacak; Mustafa Gurhan Ulusoy; M Abdurrahim Imamoglu
Journal:  ScientificWorldJournal       Date:  2012-12-23

10.  Effectiveness of Panax ginseng on Acute Myocardial Ischemia Reperfusion Injury Was Abolished by Flutamide via Endogenous Testosterone-Mediated Akt Pathway.

Authors:  Luo Pei; Hou Shaozhen; Dong Gengting; Chen Tingbo; Liu Liang; Zhou Hua
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.